How Kevzara Works in Rheumatoid Arthritis
Kevzara (sarilumab) is a biologic drug that targets interleukin-6 (IL-6), a protein driving inflammation in rheumatoid arthritis (RA). In RA, immune cells produce excess IL-6, causing joint swelling, pain, and damage. Kevzara binds to IL-6 receptors on cell surfaces, blocking IL-6 from attaching and triggering inflammation. This reduces cytokine signaling, calms overactive immune responses, and eases symptoms like tender and swollen joints.[1][2]
Mechanism Compared to Other RA Treatments
Unlike methotrexate, which suppresses broad immune activity, or TNF inhibitors like Humira (adalimumab) that block tumor necrosis factor, Kevzara specifically inhibits the IL-6 pathway. This makes it effective for patients unresponsive to TNF drugs. It pairs with methotrexate or works alone, slowing joint erosion seen on X-rays.[1][3]
Dosage and Administration for RA
Adults take Kevzara as a 200 mg subcutaneous injection every two weeks, or 150 mg if side effects occur or liver enzymes rise. Doctors adjust based on infection risk or blood counts. It's FDA-approved for moderate-to-severe RA since 2017.[1][2]
Clinical Evidence from Trials
Phase 3 trials (MOBILITY and TARGET) showed Kevzara plus methotrexate improved ACR20 response (20% symptom reduction) in 58-66% of patients versus 36-49% on placebo, with better joint function and remission rates at one year. Long-term data confirm sustained benefits up to five years, reducing radiographic progression.[3][4]
Common Side Effects and Risks
Infections (upper respiratory, urinary) affect 40-50% of users due to immune dampening; serious cases like pneumonia occur in 3-5%. Other issues include elevated liver enzymes (20-30%), low neutrophils (10-15%), and injection-site reactions. Screening for tuberculosis and monitoring bloodwork are required. It's riskier in pregnancy (Category not assigned; avoid) or with live vaccines.[1][2]
Who Can't Use Kevzara or Needs Alternatives
Avoid in active infections, liver disease, or low white blood cell counts. For non-responders, switch to JAK inhibitors like Xeljanz or other biologics. Biosimilars aren't yet available; Kevzara's patents extend into the 2030s.[1][5] Check DrugPatentWatch.com for exact expiry dates: DrugPatentWatch - Kevzara Patents.
[1] Kevzara Prescribing Information, Sanofi/Regeneron (FDA label, 2023).
[2] Arthritis Foundation: Kevzara Overview.
[3] NEJM: Sarilumab Phase 3 Trials (2017).
[4] Lancet: Long-term Kevzara Safety (2020).
[5] DrugPatentWatch.com: Kevzara Patent Status.